Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Latest Articles
Submit an article Journal homepage
0
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Immunotherapy-induced hepatitis in metastatic colorectal cancer: a systematic review and meta-analysis

Sakditad Saowapaa Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USACorrespondence, [email protected]
ORCID Iconhttps://orcid.org/0000-0002-4978-8674
, MDORCID Icon,
Natchaya Polpichaib Department of Internal Medicine, Weiss Memorial Hospital, Chicago, Illinois, USAORCID Iconhttps://orcid.org/0000-0002-3162-8912
, MDORCID Icon,
Manasawee Tanariyakulc Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USAORCID Iconhttps://orcid.org/0009-0007-1191-8780
, MDORCID Icon,
Chalothorn Wannaphutc Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USAORCID Iconhttps://orcid.org/0000-0001-8069-0408
, MDORCID Icon,
Phuuwadith Wattanachayakuld Department of Internal Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, USAORCID Iconhttps://orcid.org/0000-0003-0086-5269
, MDORCID Icon,
Pojsakorn Danpanichkula Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USAORCID Iconhttps://orcid.org/0000-0002-9121-165X
, MDORCID Icon,
Thanathip Suenghataiphorne Department of Internal Medicine, Griffin Hospital, Derby, Connecticut, USAORCID Iconhttps://orcid.org/0000-0001-7811-7960
, MDORCID Icon,
Narathorn Kulthamrongsric Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USAORCID Iconhttps://orcid.org/0000-0002-9123-7649
, MDORCID Icon,
Pharit Siladechf Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
, MD &
Lukman Tijanig Hematology and Oncology Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
, MD show all
Received 12 May 2024, Accepted 16 Jun 2024, Published online: 08 Jul 2024

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clinicians. 2019;69(1):7–34. doi:10.3322/caac.21551.
  • Maida M, Macaluso FS, Ianiro G, et al. Screening of colorectal cancer: present and future. Expert Rev Anticancer Ther. 2017;17(12):1131–1146. doi:10.1080/14737140.2017.1392243.
  • Murphy N, Moreno V, Hughes DJ, et al. Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Mol Aspects Med. 2019;69:2–9. doi:10.1016/j.mam.2019.06.005.
  • Jess T, Rungoe C, Peyrin–Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–645. doi:10.1016/j.cgh.2012.01.010.
  • Yashiro M. Ulcerative colitis-associated colorectal cancer. World J Gastroenterol. 2014;20(44):16389–16397. doi:10.3748/wjg.v20.i44.16389.
  • Roncucci L, Mariani F. Prevention of colorectal cancer: how many tools do we have in our basket? Eur J Intern Med. 2015;26(10):752–756. doi:10.1016/j.ejim.2015.08.019.
  • Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72(4):372–401. doi:10.3322/caac.21728.
  • Sutherland RL, Boyne DJ, Brenner DR, Cheung WY. The impact of BRAF mutation status on survival outcomes and treatment patterns among metastatic colorectal cancer patients in Alberta, Canada. Cancers (Basel). 2023;15(24):5748. doi:10.3390/cancers15245748.
  • Bénard F, Barkun AN, Martel M, von Renteln D. Systematic review of colorectal cancer screening guidelines for average-risk adults: summarizing the current global recommendations. World J Gastroenterol. 2018;24(1):124–138. doi:10.3748/wjg.v24.i1.124.
  • Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1(1):15065. doi:10.1038/nrdp.2015.65.
  • Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359. doi:10.6004/jnccn.2021.0012.
  • Messersmith WA. NCCN guidelines updates: management of metastatic colorectal cancer. J Natl Compr Canc Netw. 2019;17(5.5):599–601. doi:10.6004/jnccn.2019.5014.
  • Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179(4561):663–666. doi:10.1038/179663a0.
  • Rustum YM, Trave F, Zakrzewski SF, et al. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr. 1987;5(5):165–170.
  • Lee JJ, Sun W. Options for second-line treatment in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2016;14(1):46–54. https://pubmed.ncbi.nlm.nih.gov/27057668/.
  • Chibaudel B, Tournigand C, Bonnetain F, et al. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Ther Adv Med Oncol. 2015;7(3):153–169. doi:10.1177/1758834015572343.
  • Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672–680. doi:10.1200/JCO.2008.19.8135.
  • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi:10.1056/NEJMoa1104621.
  • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.
  • Borelli B, Antoniotti C, Carullo M, Germani MM, Conca V, Masi G. Immune-checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) patients beyond microsatellite instability. Cancers (Basel). 2022;14(20):4974. doi:10.3390/cancers14204974.
  • Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792. doi:10.1200/JCO.2015.66.1389.
  • Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. doi:10.1001/jamaoncol.2018.3923.
  • Vozy A, De Martin E, Johnson DB, Lebrun-Vignes B, Moslehi JJ, Salem J-E. Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. Eur J Cancer. 2019;123:112–115. doi:10.1016/j.ejca.2019.09.022.
  • Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849–861. doi:10.1016/S1470-2045(19)30027-0.
  • Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–19. doi:10.1200/JCO.19.02107.
  • André T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/NEJMoa2017699.
  • Morse MA, Overman MJ, Hartman L, et al. Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Oncologist. 2019;24(11):1453–1461. doi:10.1634/theoncologist.2019-0129.
  • Saberzadeh-Ardestani B, Jones JC, Hubbard JM, et al. Association between survival and metastatic site in mismatch repair–deficient metastatic colorectal cancer treated with first-line pembrolizumab. JAMA Netw Open. 2023;6(2):e230400. doi:10.1001/jamanetworkopen.2023.0400.
  • Kröner PT, Mody K, Farraye FA. Immune checkpoint inhibitor–related luminal GI adverse events. Gastrointest Endosc. 2019;90(6):881–892. doi:10.1016/j.gie.2019.09.009.
  • Regev A, Avigan MI, Kiazand A, et al. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020;114:102514. doi:10.1016/j.jaut.2020.102514.
  • Boyer M, Şendur MAN, Rodríguez-Abreu D, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%: randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 2021;39(21):2327–2338. doi:10.1200/JCO.20.03579.
  • Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–164. doi:10.1016/S1470-2045(09)70334-1.
  • Gudd CLC, Au L, Triantafyllou E, et al. Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. J Hepatol. 2021;75(1):177–189. doi:10.1016/j.jhep.2021.02.008.
  • Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–532. doi:10.1038/nri2343.
  • Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2(2):85–95. doi:10.1038/nri724.
  • Das R, Verma R, Sznol M, et al. Combination therapy with anti–CTLA-4 and anti–PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194(3):950–959. doi:10.4049/jimmunol.1401686.
  • Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934–949.e16. doi:10.1016/j.cell.2017.09.028.
  • Khunger M, Jain P, Rakshit S, et al. Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2018;19(3):e335–e348. doi:10.1016/j.cllc.2018.01.002.
  • Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72(2):320–341. doi:10.1016/j.jhep.2019.10.021.
  • Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. J Gastroenterol Hepatol. 2020;35(6):1042–1048. doi:10.1111/jgh.14889.
  • Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–240. doi:10.1001/jamaoncol.2015.4368.
  • Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med. 2018;168(2):121–130. doi:10.7326/M17-2073.
  • Cho YA, Han JM, Kang SY, et al. Analysis of risk factors for hepatotoxicity induced by immune checkpoint inhibitors. J Immunother. 2021;44(1):16–21. doi:10.1097/CJI.0000000000000347.
  • Kitagataya T, Suda G, Nagashima K, et al. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. J Gastroenterol Hepatol. 2020;35(10):1782–1788. doi:10.1111/jgh.15041.
  • Mizuno K, Ito T, Ishigami M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol. 2020;55(6):653–661. doi:10.1007/s00535-020-01677-9.
  • Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ Book. 2018;38(38):13–19. doi:10.1200/EDBK_100013.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.